Synapse

← Cancer Research Communications

Papers in Cancer Research Communications

Page 6 · newest first

  1. Succinate dehydrogenase B (SDHB) overexpression with enzymatic dysfunction defines a distinct subtype of undifferentiated pleomorphic sarcomaCancer Research Communications · 2025
  2. Multiplexed imaging mass cytometry reveals tumor-immune microenvironment-dependent hormone receptor expression in adult type ovarian granulosa cell tumorsCancer Research Communications · 2025
  3. Development and Application of MiMouse, a Comprehensive Genomic Profiling Panel for Credentialing Mouse Tumor ModelsCancer Research Communications · 2025
  4. Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype StratificationCancer Research Communications · 2025
  5. Initial-Care Medical and Prescription Costs for Incident Metastatic versus Non-Metastatic Colorectal CancerCancer Research Communications · 2025
  6. Efficacy and safety of nivolumab monotherapy in patients with high PD-1 positive CD8/Treg ratio in advanced NSCLC and GC: A phase II, multicenter studyCancer Research Communications · 2025
  7. Genomic landscapes of endometrioid and mucinous ovarian cancers and morphologically similar tumor typesCancer Research Communications · 2025
  8. Auranofin synergizes with cisplatin in reducing tumor burden of Notch-dependent ovarian cancerCancer Research Communications · 2025
  9. The Non-Coding Mutational Landscape of Pancreatic Cancer Reveals Recurrent Somatic Mutations in Enhancer RegionsCancer Research Communications · 2025
  10. Functional analysis of rare RAS variants of unknown significanceCancer Research Communications · 2025
  11. A First-In-Human Dose-Escalation Phase 1 Study of Basroparib (STP1002), a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid TumorsCancer Research Communications · 2025
  12. RAS pathway inhibitors combined with targeted agents are active in patient-derived spheroids with oncogenic KRAS variants from multiple cancer typesCancer Research Communications · 2025
  13. Novel Afro-Caribbean Prostate Cancer Model Reveals ancestry-specific Drug Vulnerabilities with Therapeutic Implications for Black PatientsCancer Research Communications · 2025
  14. Pancreatic cells are resistant to KRAS(Q61L) expression due to hyperactive ERK/MAPK signaling and apoptosis inductionCancer Research Communications · 2025
  15. Immune activation signatures associated with fatigue in cancer patients undergoing immune checkpoint inhibitor therapyCancer Research Communications · 2025
  16. Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for OsteosarcomaCancer Research Communications · 2025
  17. SALL4 is required for YAP1-dependent malignant and regenerative hepatocyte-to-cholangiocyte reprogrammingCancer Research Communications · 2025
  18. IPH5201, an anti-CD39 monoclonal antibody, as monotherapy or in combination with durvalumab in advanced solid tumorsCancer Research Communications · 2025
  19. Prognostic impact of immune-related adverse events on combination immune checkpoint/tyrosine kinase inhibition for metastatic renal cancerCancer Research Communications · 2025
  20. Preclinical evaluation of folate receptor-alpha chimeric antigen receptor T cells (FOLR1-CART) exhibit highly efficient anti-tumor activity against osteosarcomaCancer Research Communications · 2025
  21. GPSai: A Clinically Validated AI Tool for Tissue of Origin Prediction During Routine Tumor ProfilingCancer Research Communications · 2025
  22. Prostate-Specific Antigen Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naive Prostate Cancer PatientsCancer Research Communications · 2025
  23. Gut microbiome profiling in Eµ-TCL1 mice reveals intestinal changes and a dysbiotic signature specific to chronic lymphocytic leukemiaCancer Research Communications · 2025
  24. Plasma proteomic analysis reveals complement system changes in irradiated female BALB/c mice during mammary carcinogenesisCancer Research Communications · 2025
  25. Mutational analysis of early, low-grade bowel polyps defines a subgroup with concurrent, high-risk oncogenic drivers independent of polyp sizeCancer Research Communications · 2025
  26. Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase 1 UnitCancer Research Communications · 2025
  27. Preclinical activity of Datopotamab deruxtecan (Dato-DXd), an antibody-drug conjugate targeting TROP2, in poorly differentiated endometrial carcinomasCancer Research Communications · 2025
  28. Response to anti-angiogenic therapy is associated with AIMP protein family expression in glioblastoma and lower-grade gliomasCancer Research Communications · 2025
  29. Seclidemstat (SP-2577) induces transcriptomic reprogramming and cytotoxicity in multiple fusion-positive sarcomasCancer Research Communications · 2025
  30. Inhibition of extracellular matrix protein fibulin-3 reduces immunosuppressive signaling and increases macrophage activation in glioblastomaCancer Research Communications · 2025
  31. Drug-drug interaction liabilities with BTK inhibitor TL-895Cancer Research Communications · 2025
  32. Impact of Staging, Histological Grading, and Racial Background on Lip Cancer Survival in the United States: Insights from the SEER Database (2010-2020)Cancer Research Communications · 2025
  33. Mesenchymal stem cells expressing CES1 and soluble TRAIL activate CPT-11 and induce apoptosis in lung cancer brain metastatic lesionsCancer Research Communications · 2025
  34. Minimal impact of COVID-19 on one-year mortality on U.S. cancer patients diagnosed early in the pandemicCancer Research Communications · 2025
  35. Clinical Validity of FoundationOne Liquid CDx for Detection of BRAF V600E in Colorectal CancerCancer Research Communications · 2025
  36. Novel pre-treatment autoantibodies correlate with enfortumab vedotin-related dermatologic events in patients with advanced urothelial cancerCancer Research Communications · 2025
  37. GALNT7 stratifies dMMR/MSI colorectal cancer into distinct molecular subsets associated with prognosis and PD-L1 expressionCancer Research Communications · 2025
  38. A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3-Expressing Relapsed or Refractory Solid TumorsCancer Research Communications · 2025
  39. Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted TherapiesCancer Research Communications · 2025
  40. Phase 2 Study of Zilovertamab Vedotin in Participants With Metastatic Solid TumorsCancer Research Communications · 2025
  41. Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective AnalysisCancer Research Communications · 2025
  42. Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer StudyCancer Research Communications · 2025
  43. Collagen XVII Promotes Pancreatic Ductal Adenocarcinoma Tumor Growth through Regulation of PIK3R5Cancer Research Communications · 2025
  44. Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC ModelsCancer Research Communications · 2025
  45. One-Carbon Metabolism Inhibition Depletes Purines and Results in Profound and Prolonged Ewing Sarcoma Growth SuppressionCancer Research Communications · 2025
  46. Treatment Outcomes Differ for Racial and Ethnic Minorities with Advanced-Stage Laryngeal Cancer: A Florida Cancer Data System AnalysisCancer Research Communications · 2025
  47. ClinVar Database Evolution and Impact on Potential Pathogenic Germline Variant Reporting from Tumor Comprehensive Genomic ProfilingCancer Research Communications · 2025
  48. Glycemic Control and Prostate Cancer Mortality Risk in Veterans with Type 2 Diabetes MellitusCancer Research Communications · 2025
  49. Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and BarriersCancer Research Communications · 2025
  50. Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer ImmunotherapyCancer Research Communications · 2025